Kornimate/medical-research-clean huggingface dataset:
tunneling technique in treatment of miller's class iii gingival recession

Conditions: Gingival Recession

Summary: several surgical techniques have been proposed to correct recession defect and attain root coverage. though, the majority were executed on miller class i and ii recession defects. moreover, analysis of literature revealed only a few studies that treated miller class iii recession defects. in the current study, a new modification in the free gingival graft is proposed to provide the patient with more esthetic outcome, less pain and postoperative trauma. likewise, the proposed graft modification will combined both fgg and ctg benefits, overcome the limitations of the fgg and enhances the advantages of ctg.

in the current study, patients with miller's class iii will be randomly allocated in two groups. in the first group, gingival recession will be treated by tunneling technique with subepithelial connective tissue graft (sctg). the tunnel preparation will be performed in the recession site then the sctg will be harvested from the palate and inserted in the prepared tunnel and sutured in a coronally advanced position. equally , the second group will be treated with modified free gingival graft (mfgg). initially, after tunnel preparation in the recession site and harvesting of the free gingival graft,the proposed modification is performed by mimicking the recession defect shape and size leaving the rest of the free gingival graft deepithelialized and inserted in the prepared tunnel. then, suturing will be performed in a coronally advanced position.

Eligibility criteria:
inclusion criteria: 1. patients with healthy systemic condition. 2. buccal recession defects classified as miller class iii. 3. clinical indication and/or patient request for recession coverage. 4. o'leary index less than 20%. exclusion criteria: 1. pregnant females. 2. smokers as smoking is a contraindication for any plastic periodontal surgery. 3. unmotivated, uncooperative patients with poor oral hygiene 4. patients with habits that may compromise the longevity and affect the result of the study as alcoholism or para-functional habits.
the effect of aerobic exercise on learning after stroke

Conditions: Stroke

Summary: determine if attaining aerobic fitness is beneficial in producing cortical neuroplasticity in individuals with chronic stroke.

crossover clinical trial. experimental group undergoes 3x/wk/6 months of aerobic conditioning. control group performs usual daily activities. all participants will be assessed with cognitive and motor behavioral testing at baseline, 3, 6, 9 and 12 months.

Eligibility criteria:
inclusion criteria: * single ischemic stroke occuring 6-72 months prior * fugl-meyer score (upper + lower extremity) 45 or greater * mini mental status score of \>23 * approval of the subject's medical doctor exclusion criteria: * already performing \>20 min of cardiovascular exercise 3x/wk or more * alcohol consumption of \>2 oz. liquor, 8 oz. wine or 24 oz beer/day * cardiac history of unstable angina, recent myocardia infarction within the last 3 months, congestive heart failure, significant valve dysfunction * medical history of recent hospitalization (\> 3 months) for medical illness * symptomatic peripheral arterial occlusive disease * orthopedic or chronic pain conditions restricting exercise * pulmonary or renal failure * active cancer * unstable hypertension (\>160/100 mmhg) * diabetes mellitus (fasting glucose \> 180 ng./dk, hga1c \> 10%) that is unable to be controlled \< month * receptive or expressive aphasia as indicated on mmse * multiple strokes or other neuromuscular conditions * major depression that is untreated using the beck depression inventory
11c-choline pet/ct based helical tomotherapy as innovative treratment approach for bone metastases in prostate cancer patients.

Conditions: Prostate Cancer

Summary: the number of metastases may reflect the biological aggressiveness of the tumor and may determine the possibility of performing potential curative interventions such as surgery or high-dose targeted radiotherapy (rt). until a few years ago, the treatment of choice for metastatic prostate cancer was androgen deprivation (tda). this treatment was carried out as palliative care in order to postpone the progression of the disease or reduce symptoms. patients with prostate cancer with a limited number of metastases, similarly to patients suffering from other solid tumors, can be considered as patients with disease that has limited capacity to cause further secondary effects. in this scenario, the primary treatment in patients with carcinoma localized prostate, is characterized by radical prostatectomy, followed by measurement of prostate specific antigen (psa) during follow-up. after primary prostatectomy, psa values \> 0.2 ng/ml are indicative of disease recurrence, but it is not possible to determine whether the recurrence is local or distant. furthermore, imaging modalities, such as bone scanning and computed tomography (ct), do not have sufficient sensitivity to detect the presence of metastatic disease in patients with low psa levels. positron emission tomography/ct with 11c-choline is able to detect local or distant metastases with a sensitivity and specificity greater than 85% in patients with biochemical disease recurrence. 11c-choline pet/ct can be a valid tool both for diagnosis and for guiding radiotherapy treatments in these patients for whom it is not possible to obtain a definitive diagnosis with conventional diagnostic procedures. there are currently few studies that have described the use of 11c-choline pet/ct to guide treatment for bone metastases; the limitations of these studies concern the small number of patients and the short follow-up. the aim of this retrospective observational study was to evaluate the efficacy of 11c-choline pet/ct as a guide to the treatment of helical tomotherapy for an innovative therapeutic approach in bone metastases in a population of patients affected by prostate cancer with a limited number of metastasis.


Eligibility criteria:
inclusion criteria: * patients diagnosed with less than 3 bone lesions found on c11-choline pet/ct * availability of clinical follow-up using serial psa assays. exclusion criteria: \<18 years patients
smart phone atrial fibrillation application

Conditions: Atrial Fibrillation

Summary: patients with atrial fibrillation will have the chance to assess their disease management through an application available for free in android and ios smart devices


Eligibility criteria:
inclusion criteria: paroxysmal or persistent atrial fibrillation exclusion criteria: unable to provide informed consent unable to have 1 year of follow-up for any reason

Keywords: atrial fibrillation mobile technology
microcirculation in patients with leukemic hyperleukocytosis

Conditions: Hyperleukocytic Syndrome

Summary: hyperleukocytosis in patients with acute leukemia impacts rheology and microvascularization, leading to severe symptoms or even death. the investigators investigated whether blood stream alterations induced by hyperleukocytosis can be detected by sidestream dark-field imaging and whether they correlate with the grade of symptoms.


Eligibility criteria:
inclusion criteria: * acute leukemia * de-novo or relapsed stage * able to give consent exclusion criteria: * severe oral mucositis * unable to give consent * pregnant women * patients hospitalized for psychiatric disease
pertrial - perla® preservation solution

Conditions: Organ Transplant; Ischemic Reperfusion Injury

Summary: perla® is a cold preservation solution, with purpose to wash out, preserve during transport liver and kidney grafts in optimal conditions from the donor to the recipient. the purpose of the pertrial clinical investigation is to demonstrate the performance and safety of perla® cold preservation solution.


Eligibility criteria:
donor kidney / liver eligibility criteria: inclusion criteria: * donor kidney / liver suitable for preservation * donor age equal or over 18 years old * donor meets one of the following conditions: * donor after brain death (dbd), standard and extended criteria (scd \& ecd) * donor after circulatory death (dcd), cardiac arrest maastricht classification iii (awaiting cardiac arrest, controlled) exclusion criteria: * donor participating at the same time in another clinical investigation recipient eligibility criteria: inclusion criteria: * patient registered primary kidney or liver transplant candidate, male or female * patient ages ≥ 18 years old * patient who has signed written informed consent exclusion criteria: patient recipient will not be included if any of the following conditions exists: * prior solid organ or bone marrow transplant * multi-organ transplant * contraindications to transplantation (active infection, active malignancy, pregnant females, females intending to get pregnant, or not willing to use a secure contraceptive method) * participation in another clinical trial * patient unable to give consent

Keywords: cold preservation solution ischemic reperfusion injury organ transplant
accuracy of pulse oximeter with hypoxemic measurements

Conditions: Cyanotic Congenital Heart Disease

Summary: a study about accuracy of pulse oximeter with hypoxemic measurements (blue sensor, masimo, irvine, ca, usa) in children with cyanotic congenital heart disease


Eligibility criteria:
inclusion criteria: * clinical diagnosis of cyanotic congenital heart disease * weight 2.5kg to 30kg * undergoing general anesthesia * preoperative spo2\<97% exclusion criteria: * none
feasibility trial of a single session of crisis response planning for youth at high risk for suicide

Conditions: Suicide Prevention

Summary: the current study is a clinical trial, meaning a research study in which human subjects are prospectively assigned to one or more interventions to evaluate the effects of those interventions on health-related behavioral outcomes. specifically, male and female adolescents with current suicidal intent will be randomly assigned to receive either a 1-hour session of virtual crisis response planning (crp), a 1-hour session of in-person crp, or a 1-hour session of standard crisis risk management (treatment as usual). the feasibility and acceptability of the virtual crp, compared to in-person crp, will be assessed 14 days post-treatment. additional assessments of changes in mood, behavior, and suicidality will be collected daily for 14 days post-treatment via ecological momentary assessments. the investigators hypothesize the following: 1) virtual crp will be rated as more feasible and acceptable compared to traditional crp and treatment as usual interventions; 2) both versions of crp will be associated with changes in frequency and severity of suicidal ideation and behavior compared to treatment as usual; 3) virtual crp will be equally as effective as traditional crp at reducing suicide risk, suggesting that virtual crp is a promising scalable intervention adaptation.


Eligibility criteria:
inclusion criteria: * participant is 14-18 years old at the time of assent/consent * participant's legal guardian is willing and able to give parental permission (if 14-17 years old) * participant is able to give informed assent or consent (as applicable by age) * participant endorses current desires to make a suicide attempt as defined as answering "yes" to item #3 on the ask suicide screening question (asq) tool exclusion criteria: * factors that would interfere with data interpretation including serious medical or neurologic conditions * presence of current moderate to severe substance use disorder * lack of access to a personal smartphone * lack of fluency in english

Keywords: suicide crisis response planning ecological momentary assessments
symfony vs vivity in dim light

Conditions: Cataract

Summary: the purpose of this study is to evaluate the visual outcomes of the symfony lens and the vivity lens under mesopic lighting conditions in adult patients undergoing routine cataract surgery. participants will be asked to read a visual acuity chart at different distances in dim light.


Eligibility criteria:
inclusion criteria: 1. subject is undergoing bilateral lens extraction with implantation of an edof iol with a target refraction of plano ou. 2. gender: males and females. 3. age: 50 years and older. 4. willing and able to provide written informed consent for participation in the study 5. willing and able to comply with scheduled visits and other study procedures. 6. scheduled to undergo standard cataract surgery in both eyes, with 1 to 30 days between surgeries. 7. potential postoperative visual acuity of 0.2 logmar (20/32 snellen) or better in both eyes. exclusion criteria: 1. severe preoperative ocular pathology 2. uncontrolled diabetes. 3. use of any systemic or topical drug known to interfere with visual performance. 4. contact lens use during the active treatment portion of the trial. 5. any concurrent infectious/non-infectious conjunctivitis, keratitis, or uveitis. 6. clinically significant corneal dystrophy. 7. corneal irregularities potentially affecting visual acuity (i.e., keratoconus, corneal opacities. 8. history of chronic intraocular inflammation. 9. history of retinal detachment. 10. pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules. 11. previous intraocular surgery. 12. previous corneal refractive surgery (i.e., lasik, prk, rk). 13. subject who declined any type of presbyopia correcting iol due to concerns with visual disturbances (i.e., halos) 14. previous keratoplasty 15. severe dry eye 16. pupil abnormalities 17. subject who may reasonably be expected to require a secondary surgical intervention at any time during the study (other than yag capsulotomy, i.e., lasik) 18. any clinically significant, serious, or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results. 19. participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.
study evaluating dvs-233 in adult outpatients with major depressive disorder

Conditions: Major Depressive Disorder

Summary: primary: to compare the antidepressant efficacy and safety of subjects receiving dvs-233 sr versus subjects receiving placebo. secondary: to assess the response of subjects receiving dvs-233 sr for the clinical global evaluation, functionality, general well-being, pain, and remission (hamilton psychiatric rating scale for depression, 17-item \[ham-d\ 17\ \] \< 7) versus those subjects receiving placebo.


Eligibility criteria:
inclusion criteria: * subjects must have a primary diagnosis of major depressive disorder (mdd) * depressive symptoms for at least 30 days prior to the screening visit * minimum screening and study day -1 (baseline) scores of 20 on the hamilton psychiatric rating scale for depression (ham d\ 17\ ) exclusion criteria: * treatment with dvs-233 sr at any time in the past * treatment with venlafaxine (immediate release \[ir\] or extended release \[er\]) within 90 days of study day 1 * known hypersensitivity to venlafaxine (ir or er)

Keywords: depressive disorder, major depression, involutional
evaluation of small vessel disease by 3d-rotational angiography

Conditions: Stroke, Acute; Stroke; Small Vessel Cerebrovascular Disease; Ischemic Stroke

Summary: this study is aimed to elucidate the factors affecting the remodeling process of arteriolosclerosis under current practice recommendations. such knowledge may improve the understanding of cerebral small vessel disease (csvd) mechanism, define pharmacological therapy and suggest treatment target.

around 68 patients who have acute cerebral ischemic symptoms attributed by csvd will be recruited. stroke etiology will be determined by neurologists based on clinical syndrome, vascular imaging features and concurrent cardiovascular risks. the time window for recruitment is 4 weeks from the qualifying stroke. after an informed consent for the study, potential candidates will undergo a cranial mri and mr angiography. patients who are found to have acute or subacute lacunar infarcts (defined as an infarct diameter \< 15mm) in the territories supplied by the lateral lenticulostriate arteries, i.e. internal capsule, putamen, external capsular or corona radiata, will proceed to a 3-dimensional rotational angiography (3dra) at baseline and in 12 months. all recruited patients will receive single antiplatelet agents and statin. their cognition, mobility and treat cardiovascular risk factors based on 4 pre-specified goals (as elaborated in study procedures) will also be regularly reviewed.

Eligibility criteria:
inclusion criteria: 1. patient is chinese only 2. patient is 30 to 85 years of age, inclusive. 3. patients who have an acute lacunar infarct in diffusion-weighted mri compatible with small vessel disease in territories supplied by the lateral lenticulostriate arteries without relevant intracranial atherosclerotic stenosis ≥60%. 4. patient who has no contra-indication for the proposed imaging tests. 5. patient who understands the purpose and requirements of the study, and has an informed consent. 6. patient who has modified functional ambulation classification 4 or above. exclusion criteria: 1. stroke etiology uncertain or unrelated to small vessel disease, such as cardioembolism, moyamoya disease, icad or primary angiitis of cns. 2. bleeding propensity: active peptic ulcer disease, major systemic hemorrhage within 30 days, thrombocytopenia (platelets \ 1.5). 3. a medical condition that would not allow the patient to adhere to the protocol or complete the study. 4. patients with severe renal impairment. 5. patients who are taking warfarin and non-vitamin k antagonist oral anticoagulants would also be excluded.

Keywords: stroke small vessel disease 3d-rotational angiography ischemic stroke
lol: it's all improv after cancer! the impact of improvisational comedy on well-being among patients with cancer

Conditions: Distress; Breast Neoplasms; Quality of Life

Summary: managing distress and improving well-being is critically important for optimal survivorship care. treatment of distress leads to better adherence to treatment, better communication, fewer calls and visits to the oncologist's office, and avoidance of development of severe anxiety or depression. based on national guidelines, distress is typically managed with pharmacologic options (i.e. benzodiazepines), support groups, individual counseling, or chaplaincy services. to our knowledge, the role of a structured improvisational comedy (improv) program in reducing distress and improving well-being has never been evaluated in the oncology setting.

with over 14 million cancer survivors today in the united states comes a unique constellation of challenges and opportunities for health care providers trying to optimize health at a time when many patients are struggling and open to learning new skills for strengthening their own resiliency and ability to cope. not only does a significant subset of patients with cancer experience an increase in negative emotions, such as distress, anxiety and depression, but they often also experience a lack of positive emotions (hart 2010). managing distress and improving well-being is critically important for optimal survivorship care. treatment of distress leads to better adherence to treatment, better communication, fewer calls and visits to the oncologist's office, and avoidance of development of severe anxiety or depression (partridge, wang et al. 2003; carlson and bultz 2004; 2014). based on national guidelines, distress is typically managed with pharmacologic options (i.e. benzodiazepines), support groups, individual counseling, or chaplaincy services. to our knowledge, the role of a structured improvisational comedy (improv) program in reducing distress and improving well-being has never been evaluated in the oncology setting.

Eligibility criteria:
inclusion criteria: * female, diagnosed with breast cancer stage 1-3 (no distant metastases) * completed cancer treatment (including chemotherapy, radiation therapy, biologic treatment, and/or any combination) at least 1 month (30 days) from their last treatment and no more than 12 months (365 days) post-treatment. long term hormonal/biologic treatments are ok. * female age ≥ 18 * scores a at least 4/10 (≥4) on the national comprehensive cancer network distress thermometer * agrees to complete study surveys * agrees to attend 6 improv classes * english speaking * emotionally stable (per physician clearance) to participate in this series
incretin-based therapy in late preclinical type 1 diabetes

Conditions: Type 1 Diabetes

Summary: the objective of the trial is to study whether daily treatment with liraglutide improves endogenous insulin secretion, postpones progression to overt type 1 diabetes, and is tolerable and safe in subjects aged 10-30 years, who are positive for multiple islet autoantibodies and have dysglycemia.


Eligibility criteria:
inclusion criteria: * 10-30 years of age * positive for at least 2 islet autoantibodies * glucose intolerance or dysglycemia: impaired glucose tolerance (igt, 2-hour p-gluc 7.8-11.0mmol/l), or impaired fasting glucose (ifg, fp-gluc 6.1-6.9mmol/l), and/or 10% rise in hba1c since the last measurement (2 - 12 mo ago), and/or p-gluc at least 11.1mmol/l at 30, 60 or 90 min during ogtt * not pregnant exclusion criteria: * allergic to liraglutide or other ingredients of victoza * type 1 diabetes * diabetic ketoacidosis * previous treatment in the last three months with any antidiabetic medication * impaired liver or kidney function or on dialysis * severe heart failure * severe stomach or gut problem resulting in gastroparesis, or inflammatory bowel disease * past or current history of pancreatitis * serum calcitonin value above normal (\>50 ng/l or at least 3.4pmol/l) * presence of any chronic metabolic, hematologic or malignant disease * obesity bmi at least 30 * pregnant females and females of childbearing potential who are not using adequate contraceptive methods. * breast-feeding

Keywords: diabetes type 1 diabetes, insulin-dependent liraglutide preclinical type 1 diabetes glp-1 analogue dysglycemia prevention